Nektar Therapeutics

What Nektar Therapeutics does

Nektar Therapeutics is a clinical-stage biopharmaceutical company founded in 1990 and headquartered in San Francisco, developing a pipeline of immunotherapies centered on immune system modulation through regulatory T cell (Treg) enhancement, with a portfolio spanning autoimmune, inflammatory, and oncology indications. The company's lead candidate, rezpegaldesleukin, is an IL-2 receptor agonist designed to selectively stimulate Treg proliferation and restore immune homeostasis; it is in Phase 2b/3 development for atopic dermatitis, alopecia areata, and Type 1 diabetes, with FDA Fast Track designation in the first two indications and a Phase 3 program (ZENITH-AD) expected to initiate by July 2026. The broader pipeline includes NKTR-0165 (TNFR2 agonist, first-in-human 2026), NKTR-0166 (TNFR2 bispecific), NKTR-422 (CSF1R agonist), and NKTR-255 (IL-15 agonist for oncology combinations), all rooted in proprietary polymer conjugate chemistry technology.

Nektar has historically monetized its drug delivery and immunology platform through strategic collaborations, having generated eleven approved medicines through partnerships (including PEGASYS, MIRCERA, Neulasta, and Cimzia) and currently maintaining five active collaborations. The company is pre-commercial on its current pipeline and reports revenue of approximately $10.9 million per quarter, generated almost entirely from legacy collaboration and licensing royalties; this is dwarfed by R&D investment, with Q1 2026 net loss of $44.9 million against cash and investments of $731.6 million, providing multi-year runway following two successive public equity offerings in February and April 2026 totaling $833.8 million in gross proceeds. Capital is allocated toward Phase 3 rezpegaldesleukin development, broader pipeline advancement, and biologics process development through contract manufacturing globally.

Go-to-market for current pipeline candidates is exclusively through clinical trials, with planned future commercialization through either partnerships with larger pharmaceutical companies or direct specialty sales to healthcare providers; the company explicitly anticipates out-licensing rather than building standalone commercial infrastructure. Leadership is anchored by long-tenured CEO Howard W. Robin (joined 2007, prior CEO of Sirna Therapeutics acquired by Merck for $1.1B) and Chief R&D Officer Jonathan Zalevsky, Ph.D., with an acting CFO appointed in May 2026 amid elevated capital markets activity. The firm employs 101-250 staff and has, at various points, been subject to securities litigation tied to the REZOLVE-AA Phase 2b trial enrollment controversy, an overhang partially offset by positive 52-week extension data.

Name

Nektar Therapeutics

Legal name

Nektar Therapeutics

Website

https://nektar.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Nektar Therapeutics is a San Francisco-based clinical-stage biopharmaceutical company developing Treg-modulating immunotherapies for autoimmune, inflammatory, and oncology indications, with lead IL-2 receptor agonist rezpegaldesleukin advancing to Phase 3 in atopic dermatitis and alopecia areata.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIACAB

Immunology & Autoimmune Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAAAAAC

Cytokines, Interferons & Immunomodulatory Proteins

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAAAH

Therapeutic Peptides & Protein/Peptide Biologics

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Immunotherapy development
• Autoimmune disease therapeutics
• Regulatory T cell modulation
• Clinical-stage biopharmaceuticals
• Polymer conjugate chemistry

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Collaboration and Licensing Revenue: Nektar historically generated revenue through strategic partnerships and licensing agreements with pharmaceutical companies. The company has generated eleven approved medicines through strategic partnerships including PEGASYS, MIRCERA, Neulasta, Cimzia, and others. Currently in pre-revenue clinical stage as all drug candidates are in development.
2. Q1 2026 Revenue: Reported Q1 2026 revenue of $10.9 million, with net loss of $44.9 million. Revenue remains relatively flat as company focuses on clinical development rather than commercialized products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies that target regulatory T cells (Tregs) to restore immune homeostasis in autoimmune and inflammatory diseases. Its lead candidate rezpegaldesleukin (REZPEG) is an IL-2 receptor agonist in Phase 2b/3 development for atopic dermatitis, alopecia areata, and Type 1 diabetes. The pipeline also includes TNFR2 agonists (NKTR-0165, NKTR-0166), a CSF1R agonist (NKTR-422), and an IL-15 agonist (NKTR-255) for oncology.

Product overview

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel immunotherapies focused on autoimmune and inflammatory diseases. The company's pipeline centers on regulatory T cell (Treg) modulating biologics, with lead candidate rezpegaldesleukin (REZPEG) in Phase 2b/3 development for atopic dermatitis, alopecia areata, and Type 1 diabetes. Additional pipeline candidates include NKTR-0165 (TNFR2 agonist for MS, vitiligo, UC), NKTR-0166 (bispecific for rheumatic diseases), NKTR-422 (CSF1R agonist for fibrotic diseases), and NKTR-255 (IL-15 agonist for oncology). The company leverages proprietary immunomodulation platforms targeting IL-2 and related immune pathways.

Differentiator

Problem solved

Functional benefit

Products and services

• Rezpegaldesleukin (REZPEG)

Quantifiable outcome

• 27.6% of alopecia areata patients achieved SALT Score ≤20 at 52 weeks with rezpegaldesleukin high-dose (24µg/kg) versus 6.7% for placebo
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Multiple Pharmaceutical PartnerscoreStrategic or Co-development PartnerNektar has generated eleven approved medicines through strategic collaborations with leading pharmaceutical and biotechnology companies over more than three decades of innovation. Currently has five active collaborations. Partnered medicines include PEGASYS (Roche), MIRCERA (Roche), Neulasta (Amgen), Cimzia (UCB), and others. The company maintains a strong track record of successful global partnerships.
• Ukko LaboratoriesminorStrategic or Co-development PartnerUkko Laboratories, founded by Prof. Yanay Ofran, has a cooperation agreement with Nektar Therapeutics. Ukko is developing Ukko18, an RNA-based therapy for peanut allergies, currently in Phase 1 trials in Australia and New Zealand.
• Biolojic Design/Aulos BioscienceminorStrategic or Co-development PartnerBiolojic Design/Aulos Bioscience has cooperation agreements with Nektar Therapeutics. This company, also founded by Prof. Yanay Ofran, has an AI-designed cancer immunotherapy drug in Phase 2 human trials. Both companies have collectively raised over $200 million for research.
• MerckminorStrategic or Co-development PartnerMerck has cooperation agreements with companies that also partner with Nektar (Ukko Laboratories and Biolojic Design/Aulos Bioscience).
• TevaminorStrategic or Co-development PartnerTeva has cooperation agreements with companies that also partner with Nektar (Ukko Laboratories and Biolojic Design/Aulos Bioscience).

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Immunology leader with Rinvoq (JAK) and Skyrizi (IL-23) anchoring share in AD/alopecia-adjacent indications — sets the bar for oral/specialty uptake of a new Treg modulator.
• Bristol Myers Squibb: Already partnered with Nektar historically on IL-2 oncology programs; competitor in autoimmune via Sotyktu (TYK2) and Zeposia, defining market dynamics Nektar will enter.
• Sanofi / Regeneron (Dupixent): Dupixent dominates the atopic dermatitis market that Nektar's rezpegaldesleukin targets; comparison benchmark for efficacy, safety, and commercial scale in AD.
• Takeda Pharmaceutical Company: Major immunology player and previous employer of Nektar's R&D leadership; overlapping IL-2/inflammation research programs make it a plausible future BD counterparty.
• Eli Lilly: Immunology major with IL-13 (lebrikizumab) and IL-23 programs in atopic dermatitis, plus Taltz — direct competitive overlap in Nektar's lead indications.
• Amgen: Large immunology incumbent and long-time Nektar partner on Neulasta; develops competing IL-2/immunomodulatory franchises and biologic autoimmune therapies.
• Roche: Global pharma partner on PEGASYS/MIRCERA and pioneer in immunology; serves as benchmark for IL-2/cytokine franchise economics and partnership structure.

Direct peers

• Incyte Corporation: Specialty biotech with strong autoimmune franchise (Opzelura, Jakafi); Roy Whitfield (former Incyte CEO) sits on Nektar's board, signaling strategic adjacency in Treg/cytokine drug development.
• AnaptysBio: Clinical-stage immunology biotech developing IL-2/cytokine modulators and antibody therapeutics for autoimmune indications — most directly comparable mechanism and stage.

Emerging players

• Arcutis Biotherapeutics: Late clinical/early commercial biotech focused on inflammatory dermatology (atopic dermatitis, alopecia areata); directly competes for the same dermatology-specialty physician audience Nektar targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nektar-therapeutics
• Xx.com/NektarNews

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds11 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nektar Therapeutics